Close Menu

multiple myeloma

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Empire Genomics has discovered a genetic mutation that early studies suggest might be linked to increased response to a class of drugs called proteasome inhibitors.

NEW YORK (GenomeWeb News) – Empire Genomics today announced it has received a Phase I SBIR grant from the National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma.

NEW YORK (GenomeWeb News) – The Multiple Myeloma Research Foundation and GenoSpace today announced a partnership to create an "information ecosystem" of new discoveries in multiple myeloma to be used by researchers, clinicians, and patients.

NEW YORK (GenomeWeb News) – Empire Genomics said today that it has acquired the exclusive license to a genomic biomarker from Emory University for the development of a molecular diagnostic test for determining which therapies may be most suitable for specific patients with multiple myeloma.

NEW YORK (GenomeWeb News) – The Multiple Myeloma Research Foundation said today that it will collaborate with the US Department of Veterans Affairs in a study of the molecular and genetic causes of multiple myeloma.

NEW YORK (GenomeWeb News) – GNS Healthcare will work with researchers at Dana-Farber Cancer Institute and Mount Sinai School of Medicine to create computer models of multiple myeloma for use in developing new therapies, the data analytics firm said today.

NEW YORK (GenomeWeb News) – NextBio today announced a deal with the Winship Cancer Institute of Emory University to identify biomarkers and treatments for multiple myeloma.

NEW YORK (GenomeWeb News) – Eutropics Pharmaceuticals has received two new Small Business Innovation Research award contracts totaling $1.7 million from the National Cancer Institute to fund development of two biomarker-based companion diagnostic assays for use in cancer treatment.

NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund researchers seeking to develop and validate biomarkers that can be used to detect and predict progression of hematopoietic malignancies, such as Hodgkin and non-Hodgkin lymphoma, leukemia, multiple myeloma, and others.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.